MedTrace Logo

Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray

NCT05146206 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 426

Last updated 2024-04-12

Study results available
· View outcomes & findings →

Summary

The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).

Conditions

  • Allergic Rhinitis

Interventions

OTHER

Observational

In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.

Sponsors & Collaborators

  • Seqirus

    collaborator INDUSTRY

  • Glenmark Pharmaceuticals S.A.

    collaborator INDUSTRY

  • Community and Patient Preference Research Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Simon Fifer, PhD · Community and Patient Preference Research Pty Ltd

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-08
Primary Completion
2022-02-27
Completion
2022-02-27

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05146206 on ClinicalTrials.gov